Needham Reiterates Buy on CRISPR Therapeutics, Raises Price Target to $88
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on CRISPR Therapeutics (NASDAQ:CRSP) and raised the price target from $82 to $88.
June 09, 2023 | 4:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum reiterates a Buy rating on CRISPR Therapeutics and raises the price target from $82 to $88.
The news of Needham analyst Gil Blum reiterating a Buy rating and raising the price target for CRISPR Therapeutics is likely to have a positive short-term impact on the stock price. This is because the higher price target indicates increased confidence in the company's prospects, which may attract more investors and drive the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100